Posters

Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% eye drop in the treatment of Adenoviral Keratoconjunctivitis: results from a multicenter randomized controlled study

Poster Details

First Author: G.Giannaccare ITALY

Co Author(s):    G. Ricciardelli   A. Di Zazzo   M. Cennamo   V. Scorcia   M. Romano   R. Mencucci     

Abstract Details

Purpose:

To evaluate the effect of the use of polyvinylpyrrolidone-iodine (PVP-I) 0.6% eye drop on the clinical course of patients affected by Adenoviral Keratoconjunctivitis (AKC).

Setting:

The study was conducted in four Italian Centers: Humanitas Gavazzeni Hospital of Bergamo; University Eye Clinic of Florence; Campus Biomedico University Hospital of Rome; University Magna Græcia of Catanzaro.

Methods:

Consecutive patients with clinical signs of AKC and positive results of AdenoPlus test were enrolled. Patients were randomized to receive: PVP-I 0.6% eye drops 4 times/daily for 20 days (Group A) or hyaluronate-based tear substitutes 4 times/daily for 20 days (Group B). The following data were recorded at diagnosis (V0) and after treatment (V1): best-corrected visual acuity (BCVA), OCT pachimetry map; corneal haze; conjunctival injection and chemosis; subepithelial corneal infiltrates (SEIs); corneal and conjunctival staining; corneal densitometry. The primary outcomes were the resolution time of AKC and the incidence of SEIs.

Results:

Overall, 59 AKC patients (34 for Group A and 25 for Group B) completed the study. Patients of Group A showed a significant shorter resolution time and lower incidence of SEIs compared to patients of Group B. In particular, SEIs were present at V1 in 3/34 (8.82%) patients of the Group A vs 11/25 (44%) of the Group B (P = 0.005). Patients of Group A showed a significantly lower incidence of corneal haze compared to patients of Group B (0/34 vs 3/25; P = 0.038). No side effects were reported for both groups.

Conclusions:

The use of PVP-I 0.6% eye drop in the setting of AKC reduces the risk of SEIs as well as the resolution time of the disease without any side effect.

Financial Disclosure:

None